{
    "eid": "2-s2.0-85110221270",
    "title": "Genotyping HLA alleles to predict the development of Severe cutaneous adverse drug reactions (SCARs): state-of-the-art",
    "cover-date": "2021-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Toxicology",
            "@code": "3005",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology",
            "@code": "3004",
            "@abbrev": "PHAR"
        }
    ],
    "keywords": [
        "AGEP",
        "dress",
        "HLA",
        "pharmacogenetics",
        "pharmacogenomics",
        "SCARs",
        "SJS/TEN",
        "Thailand"
    ],
    "authors": [
        "Thawinee Jantararoungtong",
        "Therdpong Tempark",
        "Napatrupron Koomdee",
        "Sadeep Medhasi",
        "Chonlaphat Sukasem"
    ],
    "citedby-count": 12,
    "ref-count": 110,
    "ref-list": [
        "Severe cutaneous adverse drug reactions manifesting as Stevens-Johnson syndrome and toxic epidermal necrolysis reported to the national pharmacovigilance center in Nigeria: a database review from 2004 to 2017",
        "Adverse drug reactions and organ damage: the skin",
        "Pharmacogenetic testing for prevention of severe cutaneous adverse drug reactions",
        "Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population",
        "Drug hypersensitivity: pharmacogenetics and clinical syndromes",
        "Applications of immunopharmacogenomics: predicting, preventing, and understanding immune-mediated adverse drug reactions",
        "Immune-mediated adverse drug reactions",
        "Severe Cutaneous adverse drug reactions: presentation, risk factors, and management",
        "Adverse cutaneous drug eruptions: current understanding",
        "Acute generalized Exanthematous Pustulosis: pathogenesis, genetic background, clinical variants and therapy",
        "Severe cutaneous adverse reactions to drugs",
        "Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis",
        "Immunohistopathological findings of severe cutaneous adverse drug reactions",
        "Genetic markers of severe cutaneous adverse reactions",
        "Genetic variants associated with phenytoin-related severe cutaneous adverse reactions",
        "HLA association with Drug-Induced adverse reactions",
        "Pharmacogenetics of abacavir hypersensitivity: a systematic review and meta-analysis of the association with HLA-B*57:01",
        "Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir",
        "Clinical pharmacogenetics implementation consortium guidelines for HLA-B Genotype and Abacavir dosing: 2014 update",
        "Diagnostic test criteria for HLA genotyping to prevent drug hypersensitivity reactions: a systematic review of actionable HLA recommendations in CPIC and DPWG guidelines",
        "Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland",
        "Association between HLA and Stevens-Johnson syndrome induced by carbamazepine in Southern Han Chinese: genetic markers besides B*1502?",
        "Association between HLA-B alleles and carbamazepine-induced maculopapular exanthema and severe cutaneous reactions in Thai patients",
        "Medical genetics: a marker for Stevens-Johnson syndrome",
        "Association of HLA-B*1502 allele and carbamazepine-induced severe adverse cutaneous drug reaction among Asians, a review",
        "Association of HLA-BFNx011502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians",
        "HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese",
        "Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions",
        "HLA-B*57:01 confers genetic susceptibility to carbamazepine-induced SJS/TEN in Europeans",
        "Association between the HLA-B alleles and carbamazepine-induced SJS/TEN: a meta-analysis",
        "HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese",
        "Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese",
        "Association of HLA genotypes with phenytoin induced severe cutaneous adverse drug reactions in Thai children",
        "Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population",
        "HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol",
        "HLA-B*58:01 for Allopurinol-Induced Cutaneous Adverse Drug Reactions: implication for Clinical Interpretation in Thailand",
        "HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis",
        "Allopurinol hypersensitivity: investigating the cause and minimizing the risk",
        "Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans",
        "Association of human leukocyte antigen variants and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis",
        "Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing",
        "Association Between HLA-B*1301 and Dapsone-Induced Cutaneous adverse drug reactions: a systematic review and Meta-analysis",
        "The HLA-B*13:01 and the dapsone hypersensitivity syndrome in Korean and Asian populations: genotype- and meta-analyses",
        "HLA-B*13:01 and the Dapsone hypersensitivity syndrome",
        "Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population",
        "Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions",
        "Genetic Association of Co-Trimoxazole-Induced Severe cutaneous adverse reactions is Phenotype-Specific: HLA Class I genotypes and haplotypes",
        "Whole genome sequencing identifies genetic variants associated with co-trimoxazole hypersensitivity in Asians",
        "Adverse reactions to vancomycin and cross-reactivity with other antibiotics",
        "HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms",
        "Independent strong association of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe mucosal involvement",
        "HLA-B*5901 is strongly associated with methazolamide-induced Stevens\u2013Johnson syndrome/toxic epidermal necrolysis",
        "HLA-B*59:01: a marker for Stevens-Johnson syndrome/toxic epidermal necrolysis caused by methazolamide in Han Chinese",
        "Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population",
        "Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population",
        "Associations of CYP2C9 and CYP2C19 Pharmacogenetic variation with phenytoin-Induced cutaneous adverse drug reactions",
        "Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions",
        "Association analysis of CYP2C9*3 and phenytoin-induced severe cutaneous adverse reactions (SCARs) in Thai epilepsy children",
        "Genetic and clinical risk factors associated with phenytoin-induced cutaneous adverse drug reactions in Thai population",
        "HLA Alleles and CYP 2C9*3 as predictors of phenytoin hypersensitivity in East Asians",
        "Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study",
        "Causative drugs for drug-induced cutaneous reactions in central China: a 608-case analysis",
        "Epidemiology and risk factors for severe delayed drug hypersensitivity reactions",
        "Human herpes virus reactivations and dynamic cytokine profiles in patients with cutaneous adverse drug reactions --a prospective comparative study",
        "Toxic epidermal necrolysis due to zonisamide associated with reactivation of human herpesvirus 6",
        "The dynamics of herpesvirus reactivations during and after severe drug eruptions: their relation to the clinical phenotype and therapeutic outcome",
        "Mycoplasma pneumoniae with atypical stevens-johnson syndrome: a diagnostic challenge",
        "Systematic review of BRAF/MEK inhibitors-induced Severe Cutaneous Adverse Reactions (SCARs)",
        "Cutaneous adverse events of immune checkpoint inhibitors: a summarized overview",
        "Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy",
        "Human leukocyte antigen-associated severe cutaneous adverse drug reactions: from bedside to bench and beyond",
        "Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B*58:01",
        "Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools",
        "Drug-induced hypersensitivity: a 5-year retrospective study in a hospital electronic health records database",
        "Diagnostic procedures & practices in drug allergy/hypersensitivity: a survey of 13 Asian countries",
        "Pharmacogenomics guidelines: current status and future development",
        "Clinical pharmacogenetics implementation consortium guideline for HLA genotype and use of Carbamazepine and Oxcarbazepine: 2017 update",
        "2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia",
        "Cost-effectiveness of genotyping to guide treatment",
        "Economic evaluation of implementation strategies in health care",
        "Cost-effectiveness of screening for HLA-B*1502 prior to initiation of carbamazepine in epilepsy patients of Asian ancestry in the United States",
        "Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand",
        "Cost minimization of HLA-B*1502 screening before prescribing carbamazepine in Thailand",
        "Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore",
        "Is universal HLA-B*15:02 screening a cost-effective option in an ethnically diverse population? A case study of Malaysia",
        "Cost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsy",
        "The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States",
        "Cost-effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS/TEN in Thai population",
        "Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population",
        "Next-Generation sequencing based HLA typing: deciphering immunogenetic aspects of Sarcoidosis",
        "Pharmacogenomics of adverse drug reactions: implementing personalized medicine",
        "Benefit of Preemptive Pharmacogenetic Information on Clinical Outcome",
        "On the potential of preemptive genotyping towards preventing Medication-Related adverse events: results from the South Korean National Health Insurance Database",
        "Severe cutaneous adverse reactions: the pharmacogenomics from research to clinical implementation",
        "Healthcare utilization and cost of Stevens-Johnson syndrome and toxic epidermal necrolysis management in Thailand",
        "A success story in pharmacogenomics: genetic ID card for SJS/TEN",
        "Human Leukocyte Antigen Class I and Class II in Thai population: implication for clinical pharmacogenomics implementation",
        "The genomic and precision medicine in clinical practice \u2013Current perspectives and future directions",
        "Developing genomic knowledge bases and databases to support clinical management: current perspectives",
        "Preemptive pharmacogenetic testing: exploring the knowledge and perspectives of US payers",
        "Drug reimbursement decision-making in Thailand, China, and South Korea",
        "Usage pattern of Carbamazepine and Associated Severe Cutaneous Adverse Reactions in Singapore following implementation of HLA-B*15:02 genotyping as standard-of-Care",
        "Stevens-Johnson syndrome/toxic epidermal necrolysis: an Asia-Pacific perspective",
        "Allopurinol Therapy and HLA-B*58:01 genotype",
        "HLA-B*13:01 is a predictive marker of Dapsone-Induced severe cutaneous adverse reactions in Thai patients",
        "Characterization of T-Cell responses to SMX and SMX-NO in Co-Trimoxazole Hypersensitivity patients expressing HLA-B*13:01",
        "Pharmacogenomics research and its clinical implementation in Thailand: lessons learned from the resource-limited settings",
        "HLA-B allele and haplotype diversity among Thai patients identified by PCR-SSOP: evidence for high risk of drug-induced hypersensitivity"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60199578",
            "affilname": "Ramathibodi Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199578",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60020543",
            "affilname": "Bumrungrad International Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60020543",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "International Research Network-The Thailand Research Fund",
        "Ramathibodi Hospital",
        "Health System Research Institute"
    ]
}